Recent Tamoxifen Current Events | Tamoxifen News
|
|
|
Sort By:
Relevance | Page Views |
Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop. view more (2009-09-22)
Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects
Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services. view more (2009-09-21)
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor. view more (2009-08-26)
Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells
The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. view more (2009-08-10)
Breast cancer drug shows promise against serious infections
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. view more (2009-07-21)
DACH1 a key protein for tumor suppression in ER+ breast cancer
Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. view more (2009-07-15)
Study identifies how tamoxifen stimulates uterine cell growth and cancer
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth. view more (2009-07-06)
A new take on growth factor signaling in tamoxifen resistance
Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling. view more (2009-06-24)
Identifying the potential for tamoxifen resistance in patients
Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumor cells are a major cause of death. view more (2009-06-11)
VBI researchers develop new method for breast cancer biomarker discovery
Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. view more (2009-06-10)
Many breast cancer patients take high doses of antioxidants despite possible consequences
A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown. view more (2009-06-09)
Many breast cancer patients take high doses of antioxidants despite possible consequences
A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown. view more (2009-06-08)
Compliance and cost: Bitter pills to swallow in the age of oral chemotherapy
Though the growing shift toward oral chemotherapy agents offers cancer patients greater freedom and independence during their treatment, physicians say use of the new medications also poses more chances for patients to skip doses, miss prescription refills, and take their drugs in a dangerous way. view more (2009-05-29)
Mayo Clinic researchers say agent provides treatment option for women with hot flashes
A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). view more (2009-05-15)
New universal breast cancer marker predicts recurrence and clinical outcome
Reporting online in the American Journal of Pathology, researchers from the Kimmel Cancer Center at Jefferson have implicated the loss of a stromal protein called caveolin-1 as a major new prognostic factor in patients with breast cancer, predicting early disease recurrence, metastasis and breast cancer patient survival. view more (2009-05-07)
Mutation of BRCA gene influences women's views of preventive mastectomy
Women whose cells harbor harmful mutations in the BRCA genes are likely to view preventive mastectomy as the best way to reduce their risk and fears of developing breast cancer, despite other, less drastic options available. view more (2009-03-09)
Women with BRCA mutation, or worry, most likely to undergo prophylactic mastectomy
Women at increased risk for breast cancer because of the genetic BRCA mutations are more likely to think a prophylactic mastectomy is the best way to reduce their risk for the disease, compared to other women who are at high risk, according to researchers at The University of Texas M. D. Anderson Cancer Center. view more (2009-03-09)
Statin therapy ineffective in breast cancer prevention
Laboratory work in animals showed limited activity when statins were given to prevent breast cancer, according to a report in the February issue of Cancer Prevention Research, a journal of the American Association for Cancer Research. view more (2009-02-05)
Meta-analyses of global trials finds in favor of aromatase inhibitors
Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. view more (2008-12-12)
Tamoxifen chemoprevention tied to early detection of breast cancer
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute. view more (2008-10-08)
|
|
|
|
Sort By:
Relevance | Page Views |
|
